TY - JOUR
T1 - Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
AU - Seyedmousavi, Seyedmojtaba
AU - Mouton, Johan W.
AU - Verweij, Paul E.
AU - Brüggemann, Roger J.M.
N1 - Funding Information:
S Seyedmousavi has no conflict of interests. RJM Brüggemann, PE Verweij and JW Mouton have served as consultant to and have received research grants from Gilead Sciences, Merck, Astellas and Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
PY - 2013/9
Y1 - 2013/9
N2 - Voriconazole and posaconazole are extended-spectrum triazoles recommended for treatment, prophylaxis and salvage therapy of Aspergillus diseases. Over the past decade many papers have emerged supporting the use of therapeutic drug monitoring (TDM) for azole antifungals. TDM is used to tailor the exposure of a specific drug to the individuals to optimize treatment response and minimize side effects. We reviewed the pharmacokinetics and pharmacodynamics (PK-PD) characteristics of voriconazole and posaconazole. We present the available evidence on target concentrations defining maximal efficacy and minimal toxicity. Finally we provide some practical recommendations how to best perform TDM in clinical practice.
AB - Voriconazole and posaconazole are extended-spectrum triazoles recommended for treatment, prophylaxis and salvage therapy of Aspergillus diseases. Over the past decade many papers have emerged supporting the use of therapeutic drug monitoring (TDM) for azole antifungals. TDM is used to tailor the exposure of a specific drug to the individuals to optimize treatment response and minimize side effects. We reviewed the pharmacokinetics and pharmacodynamics (PK-PD) characteristics of voriconazole and posaconazole. We present the available evidence on target concentrations defining maximal efficacy and minimal toxicity. Finally we provide some practical recommendations how to best perform TDM in clinical practice.
UR - https://www.scopus.com/pages/publications/84892534686
U2 - 10.1586/14787210.2013.826989
DO - 10.1586/14787210.2013.826989
M3 - Review article
C2 - 24053274
AN - SCOPUS:84892534686
SN - 1478-7210
VL - 11
SP - 931
EP - 941
JO - Expert Review of Anti-Infective Therapy
JF - Expert Review of Anti-Infective Therapy
IS - 9
ER -